{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:44:06Z","timestamp":1785552246539,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2014M3A9D5A01073836"],"award-info":[{"award-number":["NRF-2014M3A9D5A01073836"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2017M2A2A7A02020204"],"award-info":[{"award-number":["NRF-2017M2A2A7A02020204"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2017M2A2A7A02020205"],"award-info":[{"award-number":["NRF-2017M2A2A7A02020205"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10549-020-05732-0","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T17:02:47Z","timestamp":1591894967000},"page":"591-600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["PIBF1 suppresses the ATR\/CHK1 signaling pathway and promotes proliferation and motility of triple-negative breast cancer cells"],"prefix":"10.1007","volume":"182","author":[{"given":"Eun Ji","family":"Ro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Won","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Jun","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Ho","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Jeoung","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Ho","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6640-8349","authenticated-orcid":false,"given":"Sang-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"issue":"1","key":"5732_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41571-018-0089-9","volume":"16","author":"NF Ponde","year":"2019","unstructured":"Ponde NF, Zardavas D, Piccart M (2019) Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol 16(1):27\u201344. https:\/\/doi.org\/10.1038\/s41571-018-0089-9","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"5732_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13(11):674\u2013690. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66","journal-title":"Nat Rev Clin Oncol"},{"issue":"7418","key":"5732_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"N Cancer Genome Atlas","year":"2012","unstructured":"Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61\u201370. https:\/\/doi.org\/10.1038\/nature11412","journal-title":"Nature"},{"issue":"15 Pt 1","key":"5732_CR4","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429\u20134434. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5732_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K (2019) Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov 9(2):176\u2013198. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1177","journal-title":"Cancer Discov"},{"issue":"20","key":"5732_CR6","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938\u20131948. https:\/\/doi.org\/10.1056\/NEJMra1001389","journal-title":"N Engl J Med"},{"issue":"3","key":"5732_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa1011418","volume":"364","author":"J O'Shaughnessy","year":"2011","unstructured":"O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364(3):205\u2013214. https:\/\/doi.org\/10.1056\/NEJMoa1011418","journal-title":"N Engl J Med"},{"issue":"21","key":"5732_CR8","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1007\/s00018-013-1307-3","volume":"70","author":"M Patil","year":"2013","unstructured":"Patil M, Pabla N, Dong Z (2013) Checkpoint kinase 1 in DNA damage response and cell cycle regulation. Cell Mol Life Sci 70(21):4009\u20134021. https:\/\/doi.org\/10.1007\/s00018-013-1307-3","journal-title":"Cell Mol Life Sci"},{"issue":"16","key":"5732_CR9","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1038\/emboj.2012.191","volume":"31","author":"M Thanasoula","year":"2012","unstructured":"Thanasoula M, Escandell JM, Suwaki N, Tarsounas M (2012) ATM\/ATR checkpoint activation downregulates CDC25C to prevent mitotic entry with uncapped telomeres. EMBO J 31(16):3398\u20133410. https:\/\/doi.org\/10.1038\/emboj.2012.191","journal-title":"EMBO J"},{"issue":"8","key":"5732_CR10","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.4161\/cc.8.8.8148","volume":"8","author":"D Wilsker","year":"2009","unstructured":"Wilsker D, Bunz F (2009) Chk1 phosphorylation during mitosis: a new role for a master regulator. Cell Cycle 8(8):1161\u20131163. https:\/\/doi.org\/10.4161\/cc.8.8.8148","journal-title":"Cell Cycle"},{"issue":"Pt 13","key":"5732_CR11","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1242\/jcs.086488","volume":"124","author":"M Matsuyama","year":"2011","unstructured":"Matsuyama M, Goto H, Kasahara K, Kawakami Y, Nakanishi M, Kiyono T, Goshima N, Inagaki M (2011) Nuclear Chk1 prevents premature mitotic entry. J Cell Sci 124(Pt 13):2113\u20132119. https:\/\/doi.org\/10.1242\/jcs.086488","journal-title":"J Cell Sci"},{"issue":"1","key":"5732_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ccr.2004.06.015","volume":"6","author":"MH Lam","year":"2004","unstructured":"Lam MH, Liu Q, Elledge SJ, Rosen JM (2004) Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 6(1):45\u201359. https:\/\/doi.org\/10.1016\/j.ccr.2004.06.015","journal-title":"Cancer Cell"},{"issue":"1","key":"5732_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4244","volume":"23","author":"B Huang","year":"2017","unstructured":"Huang B, Faucette AN, Pawlitz MD, Pei B, Goyert JW, Zhou JZ, El-Hage NG, Deng J, Lin J, Yao F, Dewar RS 3rd, Jassal JS, Sandberg ML, Dai J, Cols M, Shen C, Polin LA, Nichols RA, Jones TB, Bluth MH, Puder KS, Gonik B, Nayak NR, Puscheck E, Wei WZ, Cerutti A, Colonna M, Chen K (2017) Interleukin-33-induced expression of PIBF1 by decidual B cells protects against preterm labor. Nat Med 23(1):128\u2013135. https:\/\/doi.org\/10.1038\/nm.4244","journal-title":"Nat Med"},{"issue":"2","key":"5732_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0008-8749(89)90077-4","volume":"122","author":"J Szekeres-Bartho","year":"1989","unstructured":"Szekeres-Bartho J, Autran B, Debre P, Andreu G, Denver L, Chaouat G (1989) Immunoregulatory effects of a suppressor factor from healthy pregnant women's lymphocytes after progesterone induction. Cell Immunol 122(2):281\u2013294. https:\/\/doi.org\/10.1016\/0008-8749(89)90077-4","journal-title":"Cell Immunol"},{"issue":"7","key":"5732_CR15","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.21873\/anticanres.13479","volume":"39","author":"JH Check","year":"2019","unstructured":"Check JH, Check D (2019) Therapy aimed to suppress the production of the immunosuppressive protein progesterone induced blocking factor (PIBF) may provide palliation and\/or increased longevity for patients with a variety of different advanced cancers: a review. Anticancer Res 39(7):3365\u20133372. https:\/\/doi.org\/10.21873\/anticanres.13479","journal-title":"Anticancer Res"},{"issue":"2","key":"5732_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1600-0897.2010.00833.x","volume":"64","author":"J Szekeres-Bartho","year":"2010","unstructured":"Szekeres-Bartho J, Polgar B (2010) PIBF: the double edged sword. Pregnancy and tumor. Am J Reprod Immunol 64(2):77\u201386. https:\/\/doi.org\/10.1111\/j.1600-0897.2010.00833.x","journal-title":"Am J Reprod Immunol"},{"issue":"1","key":"5732_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.mehy.2008.05.042","volume":"72","author":"JH Check","year":"2009","unstructured":"Check JH, Dix E, Sansoucie L (2009) Support for the hypothesis that successful immunotherapy of various cancers can be achieved by inhibiting a progesterone associated immunomodulatory protein. Med Hypotheses 72(1):87\u201390. https:\/\/doi.org\/10.1016\/j.mehy.2008.05.042","journal-title":"Med Hypotheses"},{"key":"5732_CR18","doi-asserted-by":"publisher","first-page":"1295087","DOI":"10.1155\/2017\/1295087","volume":"2017","author":"A Gutierrez-Rodriguez","year":"2017","unstructured":"Gutierrez-Rodriguez A, Hansberg-Pastor V, Camacho-Arroyo I (2017) Proliferative and invasive effects of progesterone-induced blocking factor in human glioblastoma cells. Biomed Res Int 2017:1295087. https:\/\/doi.org\/10.1155\/2017\/1295087","journal-title":"Biomed Res Int"},{"issue":"4","key":"5732_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10571-014-0031-3","volume":"34","author":"D Kyurkchiev","year":"2014","unstructured":"Kyurkchiev D, Naydenov E, Tumangelova-Yuzeir K, Ivanova-Todorova E, Belemezova K, Bochev I, Minkin K, Mourdjeva M, Velikova T, Nachev S, Kyurkchiev S (2014) Cells isolated from human glioblastoma multiforme express progesterone-induced blocking factor (PIBF). Cell Mol Neurobiol 34(4):479\u2013489. https:\/\/doi.org\/10.1007\/s10571-014-0031-3","journal-title":"Cell Mol Neurobiol"},{"issue":"23","key":"5732_CR20","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1007\/s00018-013-1404-3","volume":"70","author":"M Halasz","year":"2013","unstructured":"Halasz M, Polgar B, Berta G, Czimbalek L, Szekeres-Bartho J (2013) Progesterone-induced blocking factor differentially regulates trophoblast and tumor invasion by altering matrix metalloproteinase activity. Cell Mol Life Sci 70(23):4617\u20134630. https:\/\/doi.org\/10.1007\/s00018-013-1404-3","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"5732_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/ijc.20326","volume":"112","author":"M Lachmann","year":"2004","unstructured":"Lachmann M, Gelbmann D, Kalman E, Polgar B, Buschle M, Von Gabain A, Szekeres-Bartho J, Nagy E (2004) PIBF (progesterone induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome. Int J Cancer 112(1):51\u201360. https:\/\/doi.org\/10.1002\/ijc.20326","journal-title":"Int J Cancer"},{"key":"5732_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jsbmb.2016.10.001","volume":"172","author":"B Marquina-Sanchez","year":"2017","unstructured":"Marquina-Sanchez B, Gonzalez-Jorge J, Hansberg-Pastor V, Wegman-Ostrosky T, Baranda-Avila N, Mejia-Perez S, Camacho-Arroyo I, Gonzalez-Arenas A (2017) The interplay between intracellular progesterone receptor and PKC plays a key role in migration and invasion of human glioblastoma cells. J Steroid Biochem Mol Biol 172:198\u2013206. https:\/\/doi.org\/10.1016\/j.jsbmb.2016.10.001","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"5732_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34(3):267\u2013273. https:\/\/doi.org\/10.1038\/ng1180","journal-title":"Nat Genet"},{"issue":"43","key":"5732_CR24","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545\u201315550. https:\/\/doi.org\/10.1073\/pnas.0506580102","journal-title":"Proc Natl Acad Sci USA"},{"key":"5732_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/1476-4598-13-141","volume":"13","author":"J Cho","year":"2014","unstructured":"Cho J, Bass AJ, Lawrence MS, Cibulskis K, Cho A, Lee SN, Yamauchi M, Wagle N, Pochanard P, Kim N, Park AK, Won J, Hur HS, Greulich H, Ogino S, Sougnez C, Voet D, Tabernero J, Jimenez J, Baselga J, Gabriel SB, Lander ES, Getz G, Eck MJ, Park WY, Meyerson M (2014) Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer 13:141. https:\/\/doi.org\/10.1186\/1476-4598-13-141","journal-title":"Mol Cancer"},{"issue":"28","key":"5732_CR26","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1038\/sj.onc.1205544","volume":"21","author":"Y Iijima","year":"2002","unstructured":"Iijima Y, Okuda K, Tojo A, Tri NK, Setoyama M, Sakaki Y, Asano S, Tokunaga K, Kruh GD, Sato Y (2002) Transformation of Ba\/F3 cells and Rat-1 cells by ETV6\/ARG. Oncogene 21(28):4374\u20134383. https:\/\/doi.org\/10.1038\/sj.onc.1205544","journal-title":"Oncogene"},{"issue":"13","key":"5732_CR27","doi-asserted-by":"publisher","first-page":"20523","DOI":"10.18632\/oncotarget.16268","volume":"8","author":"JB Demoulin","year":"2017","unstructured":"Demoulin JB, Dachy G, Arts FA (2017) Unwanted acquired mutations in Ba\/F3 transformation assays. Oncotarget 8(13):20523\u201320524. https:\/\/doi.org\/10.18632\/oncotarget.16268","journal-title":"Oncotarget"},{"issue":"22","key":"5732_CR28","doi-asserted-by":"publisher","first-page":"35488","DOI":"10.18632\/oncotarget.17828","volume":"8","author":"K Kong","year":"2017","unstructured":"Kong K, Ng PK, Scott KL (2017) Ba\/F3 transformation assays. Oncotarget 8(22):35488\u201335489. https:\/\/doi.org\/10.18632\/oncotarget.17828","journal-title":"Oncotarget"},{"issue":"8","key":"5732_CR29","doi-asserted-by":"publisher","first-page":"12596","DOI":"10.18632\/oncotarget.15392","volume":"8","author":"K Watanabe-Smith","year":"2017","unstructured":"Watanabe-Smith K, Godil J, Agarwal A, Tognon C, Druker B (2017) Analysis of acquired mutations in transgenes arising in Ba\/F3 transformation assays: findings and recommendations. Oncotarget 8(8):12596\u201312606. https:\/\/doi.org\/10.18632\/oncotarget.15392","journal-title":"Oncotarget"},{"issue":"11","key":"5732_CR30","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0025-6196(11)60669-1","volume":"84","author":"SG Holtan","year":"2009","unstructured":"Holtan SG, Creedon DJ, Haluska P, Markovic SN (2009) Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc 84(11):985\u20131000. https:\/\/doi.org\/10.1016\/S0025-6196(11)60669-1","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"5732_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/s0092-8674(00)81870-x","volume":"88","author":"AG Paulovich","year":"1997","unstructured":"Paulovich AG, Toczyski DP, Hartwell LH (1997) When checkpoints fail. Cell 88(3):315\u2013321. https:\/\/doi.org\/10.1016\/s0092-8674(00)81870-x","journal-title":"Cell"},{"key":"5732_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-1-4939-0888-2_2","volume":"1170","author":"KJ Barnum","year":"2014","unstructured":"Barnum KJ, O'Connell MJ (2014) Cell cycle regulation by checkpoints. Methods Mol Biol 1170:29\u201340. https:\/\/doi.org\/10.1007\/978-1-4939-0888-2_2","journal-title":"Methods Mol Biol"},{"issue":"2","key":"5732_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1667\/RR13515.1","volume":"181","author":"CG Broustas","year":"2014","unstructured":"Broustas CG, Lieberman HB (2014) DNA damage response genes and the development of cancer metastasis. Radiat Res 181(2):111\u2013130. https:\/\/doi.org\/10.1667\/RR13515.1","journal-title":"Radiat Res"},{"issue":"1","key":"5732_CR34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1073\/pnas.1104767109","volume":"109","author":"N Pabla","year":"2012","unstructured":"Pabla N, Bhatt K, Dong Z (2012) Checkpoint kinase 1 (Chk1)-short is a splice variant and endogenous inhibitor of Chk1 that regulates cell cycle and DNA damage checkpoints. Proc Natl Acad Sci USA 109(1):197\u2013202. https:\/\/doi.org\/10.1073\/pnas.1104767109","journal-title":"Proc Natl Acad Sci USA"},{"issue":"28","key":"5732_CR35","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1038\/onc.2010.163","volume":"29","author":"T Fishler","year":"2010","unstructured":"Fishler T, Li YY, Wang RH, Kim HS, Sengupta K, Vassilopoulos A, Lahusen T, Xu X, Lee MH, Liu Q, Elledge SJ, Ried T, Deng CX (2010) Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53. Oncogene 29(28):4007\u20134017. https:\/\/doi.org\/10.1038\/onc.2010.163","journal-title":"Oncogene"},{"issue":"20","key":"5732_CR36","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1038\/emboj.2010.218","volume":"29","author":"H Niida","year":"2010","unstructured":"Niida H, Murata K, Shimada M, Ogawa K, Ohta K, Suzuki K, Fujigaki H, Khaw AK, Banerjee B, Hande MP, Miyamoto T, Miyoshi I, Shirai T, Motoyama N, Delhase M, Appella E, Nakanishi M (2010) Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo. EMBO J 29(20):3558\u20133570. https:\/\/doi.org\/10.1038\/emboj.2010.218","journal-title":"EMBO J"},{"issue":"1","key":"5732_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/sj.leu.2403571","volume":"19","author":"F Tort","year":"2005","unstructured":"Tort F, Hernandez S, Bea S, Camacho E, Fernandez V, Esteller M, Fraga MF, Burek C, Rosenwald A, Hernandez L, Campo E (2005) Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. Leukemia 19(1):112\u2013117. https:\/\/doi.org\/10.1038\/sj.leu.2403571","journal-title":"Leukemia"},{"issue":"5","key":"5732_CR38","first-page":"2413","volume":"34","author":"JH Check","year":"2014","unstructured":"Check JH, Check D, Cohen R, Sarumi M (2014) Mifepristone causing complete remission of rapidly advancing leukemia with measurement of progesterone-induced blocking factor. Anticancer Res 34(5):2413\u20132416","journal-title":"Anticancer Res"},{"issue":"2","key":"5732_CR39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.12891\/ceog3290.2016","volume":"43","author":"JH Check","year":"2016","unstructured":"Check JH, DiAntonio G, DiAntonio A, Duroseau M (2016) The progesterone receptor antagonist mifepristone does not lower serum progesterone induced blocking factor (PIBF) in the presence of progesterone. Clin Exp Obstet Gynecol 43(2):189\u2013191","journal-title":"Clin Exp Obstet Gynecol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05732-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05732-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05732-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T22:35:00Z","timestamp":1666910100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05732-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["5732"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05732-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]},"assertion":[{"value":"6 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments were conducted with the approval of the Institutional Animal Care and Use Committee (IACUC) of the Asan Institute for Life Sciences, Korea (Approval No. 2015-02-170).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}